Evidence map›Paper›PMID 38847384›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2024

Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.

Ida Wilkens, Johanne Heine, Viktoria C Ruf, Yaroslau Compta, Laura Molina Porcel, Claire Troakes, Albert Vamanu, Sophia Downes, David Irwin, Jesse Cohen and 18 more

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Multiple system atrophy: cure and care.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Ida WilkensDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.ORCID 0009-0006-0270-0029
Johanne HeineDepartment of Neurology, Hannover Medical School, Hanover, Germany.
Viktoria C RufCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Yaroslau ComptaMovement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Catalonia, Spain.
Laura Molina PorcelNeurology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Claire TroakesBasic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Albert VamanuBasic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Sophia DownesBasic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
David IrwinDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Jesse CohenDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-2554-5181
Edward B LeeDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Christer NilssonDepartment of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.
Elisabet EnglundDepartment of Clinical Sciences, Division of Pathology instead of Neurology, Lund University, Lund, Sweden.
Mojtaba NematiDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Sabrina KatzdoblerDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.ORCID 0000-0002-3512-5984
Johannes LevinDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Alex PantelyatDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-6427-7485
Joseph SeemillerDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Stephen BergerDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
John van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Elise DopperDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Annemieke RozenmullerDepartment of Pathology, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Gabor G KovacsLaboratory Medicine Program and Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.
Nathaniel BendahanEdmond J. Safra Program in Parkinson's Disease and the Rossy Progressive Supranuclear Palsy Centre, Division of Neurology, Toronto Western Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-2167-5667
Anthony E LangEdmond J. Safra Program in Parkinson's Disease and the Rossy Progressive Supranuclear Palsy Centre, Division of Neurology, Toronto Western Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Jochen HermsCenter for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Günter HöglingerDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.ORCID 0000-0001-7587-6187
Franziska HopfnerDepartment of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.ORCID 0000-0001-6524-0281

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2019 to 2023
$18.1M
Research Training in Age-Related Cognitive DisordersT32AG027668 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2007 to 2026
$6.3M
NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG072979NIA NIH HHS T32 AG027668NIA NIH HHS U19 AG062418NINDS NIH HHS P50 NS053488
6 · The paper itself

Abstract

backgroundMultiple system atrophy is a neurodegenerative disease with α-synuclein aggregation in glial cytoplasmic inclusions, leading to dysautonomia, parkinsonism, and cerebellar ataxia.

objectiveThe aim of this study was to validate the accuracy of the International Parkinson and Movement Disorder Society Multiple System Atrophy clinical diagnostic criteria, particularly considering the impact of the newly introduced brain magnetic resonance imaging (MRI) markers.

methodsDiagnostic accuracy of the clinical diagnostic criteria for multiple system atrophy was estimated retrospectively in autopsy-confirmed patients with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration.

resultsWe identified a total of 240 patients. Sensitivity of the clinically probable criteria was moderate at symptom onset but improved with disease duration (year 1: 9%, year 3: 39%, final ante mortem record: 77%), whereas their specificity remained consistently high (99%-100% throughout). Sensitivity of the clinically established criteria was low during the first 3 years (1%-9%), with mild improvement at the final ante mortem record (22%), whereas specificity remained high (99%-100% throughout). When MRI features were excluded from the clinically established criteria, their sensitivity increased considerably (year 1: 3%, year 3: 22%, final ante mortem record: 48%), and their specificity was not compromised (99%-100% throughout).

conclusionsThe International Parkinson and Movement Disorder Society multiple system atrophy diagnostic criteria showed consistently high specificity and low to moderate sensitivity throughout the disease course. The MRI markers for the clinically established criteria reduced their sensitivity without improving specificity. Combining clinically probable and clinically established criteria, but disregarding MRI features, yielded the best sensitivity with excellent specificity and may be most appropriate to select patients for therapeutic trials. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Magnetic Resonance ImagingMultiple System AtrophyParkinson DiseaseAgedAged, 80 and overBrainFemaleHumansMaleMiddle AgedRetrospective StudiesSensitivity and SpecificitySupranuclear Palsy, Progressiveautopsy‐confirmedbrain magnetic resonance imagingMRImultiple system atrophy

Identifiers

PMID38847384
PMCPMC12403858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.